ライフサイエンスコーパス: NASBA

1 NASBA could be completed in 6.5 h versus 9 h for the Arg

2 NASBA provided a standardized tool for the detection of

3 NASBA worked fairly well to quantitate HIV-1 RNA from al

4 NASBA-ECL and NASBA-beacon were similar in sensitivity,

5 e as follows: AMPLICOR MONITOR, 100 and 73%; NASBA HIV-1 QT, 84 and 100%; NucliSens HIV-1 QT, 99 and

6 ally, each standard was used separately in a NASBA reaction; subsequently, two internal standards wer

7 y nucleic acid sequence-based amplification (NASBA) (NucliSens Basic kit; BioMerieux), reverse transc

8 g nucleic acid sequence-based amplification (NASBA) and electrochemiluminescence (ECL) analysis.

9 f nucleic acid sequence-based amplification (NASBA) and quantitative real-time reverse transcription

10 y nucleic acid sequence-based amplification (NASBA) as markers of CMV infection.

11 e nucleic acid sequence-based amplification (NASBA) assay (bioMerieux, Durham, NC) were used to deter

12 A nucleic acid sequence-based amplification (NASBA) assay for qualitative detection of human cytomega

13 e nucleic acid sequence-based amplification (NASBA) assay that incorporates molecular beacon technolo

14 e Nucleic Acid Sequence-Based Amplification (NASBA) assay to determine the relationship with neurolog

15 l nucleic acid sequence-based amplification (NASBA) assay was optimized to amplify viral RNA of all f

16 f nucleic acid sequence-based amplification (NASBA) assays for the detection of West Nile (WN) and St

17 e nucleic acid sequence-based amplification (NASBA) detection and quantification platform for rapid d

18 g nucleic acid sequence-based amplification (NASBA) from Escherichia coli, Bacillus anthracis, and Cr

19 e-nucleic acid sequence-based amplification (NASBA) in an improved non-crosslinking mode for nanodiag

20 e nucleic acid sequence-based amplification (NASBA) method was investigated by use of an inhalational

21 g nucleic acid sequence-based amplification (NASBA) methodology as described previously.

22 e nucleic acid sequence-based amplification (NASBA) reaction with two exogenous internal standards fo

23 Nucleic acid sequence-based amplification (NASBA) reactions have been demonstrated to successfully

24 A nucleic acid sequence-based amplification (NASBA) technique was used to quantify HIV-1 RNA as an in

25 l nucleic acid sequence-based amplification (NASBA) technique with which small amounts of virus RNA a

26 e nucleic acid sequence-based amplification (NASBA) using molecular beacon technology (NASBA-beacon)

27 g nucleic acid sequence based amplification (NASBA) with subsequent electrochemiluminescent detection

28 g nucleic acid sequence-based amplification (NASBA), an isothermal, primer-dependent technique.

29 , nucleic acid sequence-based amplification (NASBA), and loop-mediated isothermal amplification (LAMP

30 d nucleic acid sequence-based amplification (NASBA), have enabled detection, identification and quant

31 d nucleic acid sequence-based amplification (NASBA), standard reverse transcription PCR (RT-PCR), and

32 h nucleic acid sequence based amplification (NASBA), this assay can detect concentrations of HIV RNA

33 f nucleic acid sequence-based amplification (NASBA).

34 y nucleic-acid-sequence-based amplification (NASBA).

35 a nucleic acid sequence-based amplification (NASBA-QT) assay or the NucliSens assay.

36 NASBA-ECL and NASBA-beacon were similar in sensitivity, detecting 55 (

37 first proof of successful mRNA isolation and NASBA-based amplification of mRNA within a simple microf

38 it, and QIAGEN Ultra HIV extraction kit, and NASBA manual HIV-1 quantitative NucliSens.

39 Both RT-PCR and NASBA assays were efficient in detection of hMPV infecti

40 fected individuals were tested by RT-PCR and NASBA, 73 and 27% of CSF samples and 60 and 40% of breas

41 available kits (AMPLICOR MONITOR [Roche] and NASBA HIV-1 QT or NucliSens HIV-1 QT [Organon Teknika])

42 ce-based amplification and molecular beacon (NASBA-MB) detection system in multiplex format was devel

43 Both NASBA and qPCR showed a progressive increase in lung tis

44 Both NASBA assays were significantly more sensitive than cult

45 ere tested, and 44 were positive, 34 by both NASBA and RT-PCR and 5 each by NASBA or RT-PCR only.

46 heat shock, extraction, and amplification by NASBA were successfully detected and clearly distinguish

47 CMV late gene expression determined by NASBA was an accurate and early marker of CMV infection.

48 e, 34 by both NASBA and RT-PCR and 5 each by NASBA or RT-PCR only.

49 CMV-NASBA was performed and results compared with serology,

50 Finally, a competitive NASBA reaction between one internal standard and the wil

51 he sequences were created in two consecutive NASBA reactions using the E. coli clpB mRNA sequence as

52 ivity and specificity, suggesting the duplex NASBA assay may be useful for rapid determination of agr

53 capture probe and electrochemiluminescence (NASBA-ECL assay) and a real-time assay with 6-carboxyflu

54 rocedure, including nucleic acid extraction, NASBA, and ECL detection.

55 The mRNA serving as the template for NASBA is produced by viable C. parvum as a response to h

56 nt rental were more expensive than those for NASBA-ECL; however, time to result was shortened by 1.5

57 controls consisting of previously generated NASBA amplicons could be diluted 10(15) fold and still r

58 othermal amplification (e.g. RPA, HDA, LAMP, NASBA, RCA, ICAN, SMART, SDA).

59 ic acid sequence-based amplification method (NASBA) and Roche's Amplicor HIV-1 Monitor (reverse trans

60 hese studies indicate that the CMV pp67 mRNA NASBA assay has reproducible and sensitive performance c

61 was also carried out regarding the design of NASBA primer pairs and detection probes, as well as reac

62 amplification demonstrate the usefulness of NASBA, standard RT-PCR, and TaqMan assays, in both resea

63 without the need for molecular, e.g., PCR or NASBA, amplification.

64 without the need for molecular, e.g., PCR or NASBA, amplification.

65 ion of the target, for example, using PCR or NASBA.

66 similar to the one already found for RT-PCR, NASBA, and RT-LAMP assays.

67 Positive NASBA assay results were obtained earlier than AG-IFA or

68 eled virus-specific molecular beacon probes (NASBA-beacon assay).

69 ng electrochemiluminescently labeled probes (NASBA-ECL) for detection of enteroviruses (EV) in 133 ce

70 A Q-NASBA-oriented sample preparation cassette is originally

71 nucleic acid sequence-based amplification (Q-NASBA) microfluidic platform composed of a membrane-base

72 ple preparation cassette, and a 24-channel Q-NASBA chip for environmental investigations on aquatic m

73 is developed for simple but robust on-chip Q-NASBA assays.

74 quentially, the extract is analyzed within Q-NASBA chips that are compatible with common microplate r

75 w-up (microscopy, 1.2% vs 8.9% [P < .05]; QT-NASBA, 36.7% vs 63.3% [P < .001]).

76 t baseline was 3.6% (microscopy) and 97% (QT-NASBA).

77 ucleic acid sequence-based amplification (QT-NASBA) are increasingly used to estimate pathogen densit

78 ucleic acid sequence-based amplification (QT-NASBA).

79 f Plasmodium falciparum gametocytaemia by QT-NASBA.

80 designed previously using a novel and rapid NASBA-based method.

81 Of 42 enterovirus-positive samples, NASBA detected 39 (92.9%) and RT-PCR detected 37 (88.1%)

82 For all whole-blood specimens, NASBA identified Aspergillus-positive samples in the gro

83 logy (NASBA-beacon) was compared to standard NASBA with postamplification hybridization using electro

84 n (NASBA) using molecular beacon technology (NASBA-beacon) was compared to standard NASBA with postam

85 hanced-sensitivity bDNA, and Organon Teknika NASBA HIV-1 QT) and two in-house assays (from National G

86 The NASBA and quantitative real-time RT-PCR assays demonstra

87 The NASBA and quantitative real-time RT-PCR assays detect LA

88 The NASBA assay can be used reliably to determine HIV RNA le

89 The NASBA assay detected clinically relevant recombinant vir

90 The NASBA assay had a lower limit of detection of 100 copies

91 The NASBA assay had a specificity of 100% based on the negat

92 The NASBA assay involved the use of silica to extract viral

93 The NASBA assay was able to detect dengue viral RNA in the c

94 The NASBA assays demonstrated exceptional sensitivities and

95 The NASBA primers as well as the ECL probes were highly spec

96 The NASBA-gold nanoprobe method was improved to lower the ov

97 The overall agreement between the NASBA assay and current reference tests was 86% when act

98 nce in estimated RNA copy number between the NASBA-QT assay and the AMPLICOR HIV-1 MONITOR test for i

99 e C6/36 assay, 66 were found positive by the NASBA assay, for a sensitivity of 98.5%.

100 m CMV-negative patients were negative by the NASBA assay, while 90% (10 of 11) of patient specimens t

101 cell culture or AG-IFA were positive by the NASBA assay.

102 ive) clinical specimens were positive by the NASBA assay.

103 During the NASBA reaction, a generic sequence is attached to all RN

104 e AMPLICOR HIV-1 MONITOR test and either the NASBA-QT assay or the NucliSens assay.

105 que detection formats were developed for the NASBA assays: a postamplification detection step with a

106 aving to separate the amplified RNA from the NASBA mixture.

107 es sandwich hybridization by hybridizing the NASBA-generated amplicon between capture probes and repo

108 observed with CSF or CVL, nor in any of the NASBA assays.

109 the standard AMPLICOR test (12 of 19) or the NASBA assay (10 of 25).

110 ucleic acid extraction and purification, the NASBA reaction, amplification, and detection probes.

111 y nucleic acid amplification technology (the NASBA HIV-1 RNA QT system) was investigated.

112 These results indicate that the NASBA assay is a promising assay for the early diagnosis

113 human plasma spiked with dengue viruses, the NASBA assay had a detection threshold of 1 to 10 PFU/ml.

114 a HIV-1 RNA levels were quantitated with the NASBA HIV-1 RNA QT System from blood specimens that were

115 TaqMan assays, and standard RT-PCR, with the NASBA-beacon assay yielding results in less than 1 h.

116 The sensitivities and specificities of these NASBA assays were compared to those of a newly described

117 The analytical sensitivity of the real-time NASBA assay was <1 CFU/assay.

118 Real-time NASBA is highly sensitive and useful for the detection o

119 Real-time NASBA-beacon reagents and equipment rental were more exp

120 The multiplex real-time NASBA-MB assay provides a valuable platform for the rapi

121 ue to the unique synthesis process using two NASBA reactions rather than traditional cloning techniqu

122 in a surrogate organism and amplified using NASBA.

123 acted, purified, and finally amplified using NASBA.

124 A similar analysis using NASBA with paired blood plasma and CVL, saliva, or semin

125 This new rapid construction method via NASBA provides advantages over the traditional technique

126 r prepared panels (n = 24) was compared with NASBA HIV-1 RNA QT (an earlier version of NucliSens HIV-

127 amplified in a water bath for 60-90 min with NASBA, an isothermal technique that specifically amplifi